Table 1.

Overview of patient and sample demographics in final dataset

		CheckMate 038	CheckMate 064	CheckMate 067	Gide, et al.	Liu, et al.	Van Allen, et al.	Aggregate
Patients with melanoma
Sex	N
	female	30	9	18	26	59	13	155
	male	35	33	41	48	83	27	267
Age	median (min-max)	56 (22–89)	62.5 (30–84)	58 (34–85)	61.5 (24–90)	NA	61 (22–83)	59 (22–90)
Melanoma subtype	N
	cutaneous	44	34	55	60	104	36	333
	unknown	12	0	2	7	18	2	41
	mucosal	7	3	0	2	10	2	24
	acral	2	1	2	5	10	0	20
	uveal	5	4	0	0	0	0	9
Treatment	N
	anti-PD-1	70	0	21	41	142	0	274
	anti-CTLA-4	0	0	21	0	0	40	61
	Combo (anti-PD-1 and anti-CTLA-4)	0	0	17	33	0	0	50
	anti-CTLA-4 to anti-PD-1	0	23	0	0	0	0	23
	anti-PD-1 to anti-CTLA-4	0	19	0	0	0	0	19
Patients with tumors treated with anti-PD-1 therapy
Prior ICI	N
	anti-CTLA-4 experience	39	0	0	0	58	0	97
	anti-CTLA-4 naive	31	0	21	41	84	0	177
Response	N
	CR	3	0	5	4	17	0	29
	PR	12	0	5	15	37	0	69
	SD	24	0	4	6	23	0	57
	PD	31	0	7	16	65	0	119
Timepoint	N
	Baseline	68	0	21	41	142	0	272
	On-therapy	61	0	0	9	0	0	70